<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Chem</journal-id><journal-id journal-id-type="iso-abbrev">BMC Chem</journal-id><journal-title-group><journal-title>BMC Chemistry</journal-title></journal-title-group><issn pub-type="epub">2661-801X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410841</article-id><article-id pub-id-type="pmc">PMC12101028</article-id><article-id pub-id-type="publisher-id">1497</article-id><article-id pub-id-type="doi">10.1186/s13065-025-01497-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Cutting-edge assays for mirabegron and tadalafil combo therapy for benign prostatic hyperplasia; insilico kinetics approach; multi trait sustainability assessment</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Aboras</surname><given-names>Sara I.</given-names></name><address><email>Sara.ismail.aborass@alexu.edu.eg</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Abdelhakim</surname><given-names>Mohamed R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Maher</surname><given-names>Hadir M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Youssef</surname><given-names>Rasha M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00mzz1w90</institution-id><institution-id institution-id-type="GRID">grid.7155.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2260 6941</institution-id><institution>Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, </institution><institution>University of Alexandria, </institution></institution-wrap>Elmessalah, Al-mesallah, Alexandria, 21521 Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00mzz1w90</institution-id><institution-id institution-id-type="GRID">grid.7155.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2260 6941</institution-id><institution>Alexandria&#x02019;s Main University Hospital, </institution><institution>University of Alexandria, </institution></institution-wrap>Alexandria, Egypt </aff><aff id="Aff3"><label>3</label>Faculty of Pharmacy, Alamein International University, Alamein, Matrouh Egypt </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>19</volume><issue>1</issue><elocation-id>140</elocation-id><history><date date-type="received"><day>23</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>1</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The combination therapy of mirabegron (MIR) and tadalafil (TAD) has gained significant attention in clinical practice for the treatment of Benign Prostatic Hyperplasia as well as overactive bladder syndrome. This study demonstrates the development and validation of two analytical methods for the concurrent determination of tadalafil and mirabegron in their synergistic combo therapy. Spectrophotometry and stability-indicating HPLC were employed for the accurate quantification of both drugs. The spectrophotometric methods were based on derivative, Fourier and ratio derivative of the two drugs, providing simpler, rapid alternatives for routine analysis. The stability-indicating HPLC method was developed using a reverse-phase column with a methanol-phosphate buffer gradient mobile phase, achieving optimal separation with detection at 250 nm for MIR and 225 nm for TAD. Forced degradation studies were performed under acidic, basic, oxidative, neutral, thermal, and photolytic conditions, confirming the method&#x02019;s ability to quantify MIR and TAD in presence of degradation products and establish drug stability. Both techniques were validated based on ICH guidelines, demonstrating excellent linearity, precision, accuracy, and sensitivity. The methods were successfully applied to the analysis of bulk powder and in dosage forms. Both methods were evaluated and found to be environmentally friendly, receiving approval as &#x0201c;green&#x0201d; according to the AGREE (Assessment Tool for Greenness) method, &#x0201c;white&#x0201d; under the RGB12 criteria, and &#x0201c;blue&#x0201d; according to the BAGI (Blue Analytical Greenness Index). These evaluations demonstrate the sustainability and eco-friendliness of the proposed analytical techniques. Furthermore, artificial intelligence was employed through an online tool to ensure that there were no potential drug-drug interactions between MIR and TAD, offering an additional layer of safety in clinical applications. This research contributes to the enhancement of quality control for patients undergoing combination therapy with MIR and TAD and stability testing.</p><sec><title>Graphical Abstract</title><p id="Par2">
<graphic position="anchor" xlink:href="13065_2025_1497_Figa_HTML" id="MO10"/>
</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13065-025-01497-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Mirabegron</kwd><kwd>Tadalafil</kwd><kwd>HPLC</kwd><kwd>Spectrophotometry</kwd><kwd>Benign prostatic hyperplasia</kwd><kwd>Sustainability</kwd></kwd-group><funding-group><award-group><funding-source><institution>Alexandria University</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Switzerland AG 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par3">Benign prostatic hyperplasia (BPH) as well as overactive bladder syndrome (OAB) are extremely common disorders that often result in lower urinary tract symptoms (LUTS) and a decreased quality of life, especially in the elderly [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par4">Based on&#x000a0;autopsy studies, the age-specific prevalence of BPH is estimated to be 8% in the fourth decade, 50% in the sixth, and 80% in the ninth decade of life [<xref ref-type="bibr" rid="CR2">2</xref>]. On the other hand, it has been observed that OAB symptoms in men are frequently triggered by a bladder outlet obstruction brought on by BPH and they are treated accordingly [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par5">For BPH, phosphodiesterase type 5 inhibitors, or PDE5-Is, are the first-line of treatment through relaxation of smooth muscles, increasing pelvic blood perfusion, and probably modifying afferent nerve activity. Several countries have legalized the use of tadalafil (TAD), a PDE5-I, for the treatment of LUTS/BPH, and prior randomized studies have demonstrated that its efficacy is comparable to that of &#x003b1;1-blockers [<xref ref-type="bibr" rid="CR4">4</xref>]. Although TAD may alleviate OAB and other voiding and storage symptoms, OAB symptoms could still persist in some cases. Thus, several combination treatments or add-on therapies have been revealed to be beneficial for these patients. Anticholinergics were the most commonly utilized combination, and treating OAB symptoms brought on by BPH with these medications can be helpful [<xref ref-type="bibr" rid="CR5">5</xref>]. However, adding anticholinergics may have a number of negative consequences, including dry mouth, constipation, impaired vision, and a loss in cognitive function and hence, alternative therapeutic approaches need to be thought of. As a result, Mirabegron (MIR), a &#x003b2;3-adrenoceptor (AR) agonist, has been found to be as effective as anticholinergics in treating OAB associated with BPH. However, it has fewer side effects, such as constipation and dry mouth, and is more affordable and palatable [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par6">Recent studies have proved that combo therapy or co-administration of TAD with MIR was efficient, and its safety was found to be on par with TAD mono-treatment in patients with BPH suffering from persistent storage symptoms [<xref ref-type="bibr" rid="CR6">6</xref>]. Therefore, TAD plus MIR, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, is promising effective treatment option, and it can enhance quality of life in BPH patients. Furthermore, among individuals with OAB brought on by BPH, the efficacy of TAD/MIR combo therapy seemed to be greater than that of TAD monotherapy and is linked to a decreased incidence of LUTS [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Chemical structures of <bold>A</bold> Mirabegron and <bold>B</bold> Tadalafil</p></caption><graphic xlink:href="13065_2025_1497_Fig1_HTML" id="MO1"/></fig></p><p id="Par7">For figuring out a combo therapy&#x02019;s expiration date and storage requirements, stability studies are essential. Patient safety and product quality are impacted by their analysis and testing of crucial quality factors. It is advised to conduct stress testing to concentrate on important quality factors, such as exposure to acid/base, humidity, temperature, oxidizers, and transportation extremes. Chromatographic methods are preferred in stability investigations because they can separate analytes completely in presence of degradation products in reasonable run times [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par8">For the determination of MIR, the literature reviews had shown many analytical techniques in bulk, pharmaceutical dosage forms, and biological fluids, alone or with other drugs, including spectrophotometric [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], spectrofluorometric [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], LC&#x02013;MS/MS [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>], LC-DAD [<xref ref-type="bibr" rid="CR17">17</xref>], HPTLC [<xref ref-type="bibr" rid="CR18">18</xref>], and electrochemical approaches [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par9">Numerous analytical techniques analyzed TAD either alone or together with other drugs, such as spectrophotometric [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>], spectrofluorimetric [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>],.voltametric [<xref ref-type="bibr" rid="CR25">25</xref>], HPTLC [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], LC-DAD [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], LC-FLD [<xref ref-type="bibr" rid="CR28">28</xref>], and LC&#x02013;MS/MS [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par10">Literature review reveals no reports regarding the concurrent determination of MIR and TAD. Consequently, the invention and validation of spectrophotometric and stability-indicating chromatographic techniques for the concurrent determination of TAD and MIR for quality control purposes will be the main emphasis of this study.</p><p id="Par11">While the spectrophotometric techniques comprised derivative spectra of absorption curves (D), ratio derivative (RD) and Fourier functions convolution of absorption spectra (FF), the chromatographic assay utilized gradient elution for separating this combo therapy. The referenced drugs' mixes in dosage forms were effectively determined using the suggested methods.</p><p id="Par12">Additionally, different greenness, whiteness and blueness assessment tools were used to compare and assess the methods&#x02019; sustainability. Moreover, <italic>insilico</italic> approach was utilized to evaluate any potential drug-drug interactions (DDIs) between TAD and MIR to ensure both safety and efficacy as the cited papers mentioned their synergistic effect at the pharmacodynamics level [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p></sec><sec id="Sec2"><title>Experimental</title><sec id="Sec3"><title>Materials and reagents</title><p id="Par13">MIR reference standard was purchased from Sigma-Aldrich<sup>&#x000ae;</sup> (Purity 99.6%). TAD reference standard was provided by <italic>Al-Andalous</italic> Pharma, Cairo, Egypt (Purity 98.2%). The commercial products, Bladogra<sup>&#x000ae;</sup> (by APEX pharma, New Cairo, Egypt) containing 25 mg MIR and Diamonrecta<sup>&#x000ae;</sup> (by EVA PHARMA, Giza, Egypt) containing 20 mg TAD were purchased from the Egyptian market. HPLC-grade methanol (MeOH) as well as acetonitrile (ACN) were obtained from Baker, Ireland. Triethyl amine (TEA) was purchased from Sigma-Aldrich<sup>&#x000ae;</sup>. Hydrochloric acid (HCl) and sodium hydroxide (NaOH) of analytical quality were supplied by El-Nasr Chemical Industry Company in Egypt. Additionally, 20% hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) was also&#x000a0;acquired from El-Nasr Chemical Industry Company. Distilled water was obtained via simple distillation using water distillator.</p></sec><sec id="Sec4"><title>Apparatus</title><sec id="Sec5"><title>Spectrophotometer</title><p id="Par14">A Shimadzu UV-1800 PC, Kyoto, Japan spectrophotometer (UV&#x02013;Vis double beam) utilized to do the spectrophotometric measurements and was outfitted with matched quartz cells with corresponding 1 cm path lengths.</p></sec><sec id="Sec6"><title>HPLC</title><p id="Par15">A computer running Agilent ChemStation software was linked to the HPLC&#x02013;DAD system, which included an Agilent 1260 series (Agilent Technologies, Santa Clara, CA, USA) with multiple wavelength diode array detectors G1315C/D and G1365C/D, an automated injector, a quaternary pump, and a vacuum degasser. The Agilent Eclipse Plus C<sub>18</sub> (4.6&#x02009;&#x000d7;&#x02009;100 mm&#x02009;&#x000d7;&#x02009;3.5 &#x000b5;m) column was utilized.</p></sec></sec><sec id="Sec7"><title>Stock solutions</title><p id="Par16">Stock solutions were prepared in HPLC-grade MeOH to get a 1000&#x000a0;&#x000b5;g/mL of MIR and TAD. The prepared MIR and TAD stock solutions were kept at 4&#x000b0;C in refrigerator for almost one week.</p></sec><sec id="Sec8"><title>General procedure</title><sec id="Sec9"><title>Construction of calibration curves</title><sec id="Sec10"><title>Spectrophotometry</title><p id="Par17">Different portions of the methanolic stock solutions (1000&#x000b5;g/mL) for each drug were moved to a set of 10 mL-volumetric flasks to prepare MIR/TAD calibration sets in the range 1&#x02013;20&#x000a0;&#x000b5;g/mL for both drugs then completed to their marks with distilled water.</p></sec><sec id="Sec11"><title>HPLC</title><p id="Par18">For chromatographic analysis, linearity solutions were prepared in 10 mL-volumetric flasks by accurately transferring set volumes of stock solutions for each drug and then completing to the mark with the starting ratio of the mobile phase to get a series of MIR and TAD concentrations in the range 0.85&#x02013;100&#x000a0;&#x000b5;g/mL for MIR and 0.65&#x02013;100&#x000a0;&#x000b5;g/mL for TAD.</p></sec></sec></sec><sec id="Sec12"><title>Synthetic mixtures</title><p id="Par19">For spectrophotometry, accurate volumes of stock solutions were moved to a set of 10 mL-volumetric flasks and then completed to the mark with distilled water to get mixtures of the following concentrations 20, 2 &#x000b5;g/mL, 10, 10 &#x000b5;g/mL and 3, 15 &#x000b5;g/mL for MIR and TAD, respectively. Similarly, the same procedure was done with the chromatographic method but the final dilution was performed using the same diluting solvent or the starting ratio of mobile phase used for construction of calibration curves.</p></sec><sec id="Sec13"><title>Analysis of dosage forms</title><p id="Par20">For both spectrophotometry and HPLC, ten tablets of each Bladogra<sup>&#x000ae;</sup> and Diamorecta<sup>&#x000ae;</sup> were weighted, crushed, and the corresponding weight of 50 mg MIR and 5 mg TAD were underwent a rigorous homogenization process using mechanical mixing to ensure uniform analyte distribution. Then this mix was transferred in 50-mL volumetric flask. Around 30 mL MeOH was then transferred to extract both drugs by sonication for 20 min followed by completing the volume to the mark with MeOH. The filtration protocol was carefully optimized to ensure complete removal of insoluble excipients from the dosage form. A 0.45 &#x000b5;m PTFE membrane filter was selected based on its chemical compatibility and ability to effectively remove particulate matter without affecting analyte recovery. To confirm the absence of significant analyte adsorption onto the filter, a recovery study was conducted. Known concentrations of MIR and TAD were filtered through the selected membrane, and the drug content was measured before and after filtration. The recovery rates were found to be 98.7% for MIR and 99.2% for TAD, indicating negligible adsorption. These results demonstrate that the filtration protocol is both effective and reliable for dosage form analysis. After filtration of the tablets extract, accurate volume of the extract was diluted to get 20 and 2 &#x000b5;g/mL for MIR and TAD, respectively to be analyzed using the proposed methods.</p></sec><sec id="Sec14"><title>Experimental conditions</title><sec id="Sec15"><title>Spectrophotometry</title><sec id="Sec16"><title><italic>First derivative spectrophotometry (</italic><sup><italic>1</italic></sup><italic>D)</italic></title><p id="Par21">The first derivative spectra <sup>1</sup>D (with &#x02206;&#x003bb; of 2 nm) of MIR and TAD standard solutions and the synthetic mixtures were recorded vs blank. For MIR, there was no point of zero crossing for TAD to analyze MIR. However, the <sup>1</sup>D at 294 nm (zero-crossing point for MIR) was measured then plotted against the concentrations of TAD to get its calibration graph.</p></sec><sec id="Sec17"><title>Fourier function convolution spectrophotometry (A/FF)</title><p id="Par22">This Fourier function convolution spectrophotometry (A/FF) depends on convolution of the zero-order UV spectra of MIR and TAD standards and their synthetic mixtures by combined trigonometric Fourier functions using the following equation for 8 consecutive wavelengths measured at 1 nm interval:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="d33e433">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${t{\prime}}_{r}= [( + 1.707){Ar}_{0}+ ( + 0.707){Ar}_{1} + ( - 0.707){Ar}_{2} +(- 1.707){Ar}_{3} + ( - 1.707){Ar}_{4} + ( - 0.707){Ar}_{5} +( + 0.707){Ar}_{6} + ( + 1.707){Ar}_{7}]/4$$\end{document}</tex-math><mml:math id="d33e439" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#x02032;</mml:mo></mml:mrow><mml:mi>r</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>+</mml:mo><mml:mn>1.707</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">Ar</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>+</mml:mo><mml:mn>0.707</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">Ar</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>-</mml:mo><mml:mn>0.707</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">Ar</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>-</mml:mo><mml:mn>1.707</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">Ar</mml:mi></mml:mrow><mml:mn>3</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>-</mml:mo><mml:mn>1.707</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">Ar</mml:mi></mml:mrow><mml:mn>4</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>-</mml:mo><mml:mn>0.707</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">Ar</mml:mi></mml:mrow><mml:mn>5</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>+</mml:mo><mml:mn>0.707</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">Ar</mml:mi></mml:mrow><mml:mn>6</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>+</mml:mo><mml:mn>1.707</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">Ar</mml:mi></mml:mrow><mml:mn>7</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo stretchy="false">/</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:math><graphic xlink:href="13065_2025_1497_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>where t&#x02019;<sub>r</sub> is the Fourier function coefficient and eight zero-order absorption values are represented by Ar0-Ar7. The specified combined FF, which were computed as follows, are shown by the numbers in parenthesis:</p><p id="Par23">T&#x000b4;&#x02009;=&#x02009;[cos x&#x02009;+&#x02009;cos (x&#x02009;+&#x02009;45)] (2).</p><p id="Par24">FF coefficients were recoded at 252 nm (TAD zero crossing) to determine MIR. Similarly, the coefficients were also recorded at 292 nm (zero crossing of MIR) and were used for the determination of TAD. By connecting the FF coefficients determined at the chosen sites to the relevant component concentration, calibration curves as well as the regression equations produced from them were created.</p></sec><sec id="Sec18"><title><italic>Ratio derivative spectrophotometry (R</italic><sup><italic>1</italic></sup><italic>D)</italic></title><p id="Par25">To obtain MIR concentration, the absorption spectra of MIR/TAD mixtures were divided by those of standard TAD (1 &#x003bc;g/mL). The R<sup>1</sup>D was then recorded to determine MIR concentrations at 246 and 258 nm (peak to peak). Similarly, for the same MIR/TAD mixtures, were divided by that of standard MIR (10 &#x003bc;g/mL). The R<sup>1</sup>D of the ratio spectra was then recorded to determine TAD concentrations at 287 and 297 nm (peak to peak).</p></sec></sec><sec id="Sec19"><title>Chromatographic conditions</title><p id="Par26">An Agilent Eclipse Plus -C<sub>18</sub> analytical column (100&#x02009;&#x000d7;&#x02009;4.6 mm, 3.5 &#x000b5;m) was used for the separation process. For the first three min, the gradient mobile phase system was set up with 40: 60% (v/v), solvent A (phosphate buffer 10 mM, pH 7 with triethylamine, 1% (v/v)): solvent B (MeOH) followed by step change to&#x000a0;20:80, v/v, respectively for two min. At 5 min, the system returned to the initial ratio of the mobile phase to permit column equilibration before the next injection. A membrane filter with a pore size of 0.45 &#x000b5;m was used to filter the buffer, and 25 &#x000ba;C was the setting for the temperature during the run. Using DAD, the detection wavelength was tuned at 250 nm for MIR and 225 nm for TAD. With an injection volume 10-&#x000b5;L and a flow rate 1 mL/min, the run duration was 6 min in total. The 10 &#x000b5;L injection volume was selected after evaluating different volumes (5&#x02013;20 &#x000b5;L) to balance sensitivity, peak shape, and solvent consumption. Ten &#x000b5;L volume led to reduce solvent consumption while maintaining peak integrity. Volumes lower than 10 &#x000b5;L led to lower response with peak distortion. A combination 80:20 MeOH: Water in a volume of 100 &#x000b5;L as washing solution of the needle between injections effectively dissolves TAD (highly organic-soluble) and the water-soluble MIR and thus eliminated carry over effect.</p></sec></sec><sec id="Sec20"><title>Forced degradation and stability studies</title><p id="Par27">Forced degradation tests were performed on MIR and TAD separately and in mixture using&#x000a0;working solutions (500 &#x000b5;g/mL for each) with an&#x000a0;amount&#x000a0;of 1 mL. After degradation, the solutions were neutralized, if needed, followed by completing with distilled water to the full level in 10-mL volumetric flasks series. A final concentration of 50 &#x000b5;g/mL was achieved for both MIR and TAD. Each degradation condition was done in replicates.</p><sec id="Sec21"><title>Acidic and basic hydrolysis</title><p id="Par28">For acidic and basic hydrolysis, respectively, 1 mL volumes of 1 M HCl or 1 M NaOH were added to the MIR and TAD solutions. After that, the solutions were heated in a thermostatic water bath at 90 &#x000b0;C for one hour for both basic and acidic hydrolysis. After the specific time, the solutions have been cooled and then neutralized to pH 7 at the predetermined intervals. Degraded solutions were diluted with distilled water in 10-mL volumetric flasks.</p></sec><sec id="Sec22"><title>Neutral hydrolysis</title><p id="Par29">1 mL of distilled water was added to the MIR and TAD solutions. The mixture was heated up in a water bath at 90 &#x02103; for 1 h, then cooled and completed to the volume and concentration specified above.</p></sec><sec id="Sec23"><title>Oxidative degradation</title><p id="Par30">MIR and TAD solutions were treated with 1 mL of hydrogen peroxide (6% v/v) and kept at room temperature for 1 h. The solutions were then diluted as described above.</p></sec><sec id="Sec24"><title>Photolytic degradation</title><p id="Par31">Photo-stability was conducted by exposing MIR and TAD stock solutions (1 mL, 500 &#x000b5;g/mL) to light for 24 h. Following the mentioned period, the volume was diluted, as illustrated above.</p></sec><sec id="Sec25"><title>Dry heat</title><p id="Par32">In a controlled-temperature oven, a precise weight of 10 mg of the powdered MIR and TAD, both alone and in combination, were maintained for one hours at 90&#x02009;&#x000b1;&#x02009;1&#x000b0;C. Following the specified amount of time, the treated powder was dissolved in methanol in a 10-mL volumetric flask to form a 500-&#x003bc;g/mL stock solution. One mL was then further diluted 10 times using distilled water before being added to the HPLC system.</p></sec></sec></sec><sec id="Sec26"><title>Results and discussion</title><p id="Par33">The combination of MIR and TAD combo therapy demonstrated a synergistic strategy in the treatment of LUTS/BPH and LUTS/OAB. For quality control purposes, simultaneous determination of the two medicines is crucial. Different analytical techniques were suggested for the concurrent determination of MIR and TAD: spectrophotometric based methods, A/FF, R<sup>1</sup>D, and an HPLC method. On the other hand, one UV spectrophotometric technique, <sup>1</sup>D, was proposed for TAD analysis alone. To extend the applicability of our HPLC method to stability-indicating property and to ensure safe combinations of these medications, a stress study was performed and succeeded in separating the drugs from degradation products.</p><sec id="Sec27"><title>Method optimization</title><sec id="Sec28"><title>Spectrophotometric optimization</title><p id="Par34">The MIR and TAD absorption spectra revealed great overlap during their determination in the reported therapeutic dose of 10:1 for MIR and TAD, respectively, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. Thus, the concurrent determination of the two drugs was difficult using direct absorption spectra. Accordingly, a variety of mathematical techniques for manipulating absorbance data were tested in order to achieve spectral resolution without requiring pre-separation steps. Three methods were proposed, the first one depended on derivative spectra of absorption curves, the second used trigonometric FF for spectral convolution, and the last used ratio spectra of derivative absorption curves.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>zero order spectra of MIR &#x00026; TAD at their therapeutic dosage ratio (10:1)</p></caption><graphic xlink:href="13065_2025_1497_Fig2_HTML" id="MO2"/></fig></p><p id="Par35">It is important to highlight that water, EtOH, and MeOH were examined as diluting solvents. Water was the ideal solvent for the analytical and environmentally friendly requirements in proposed methods. MeOH and EtOH produced similar intensities for both drugs but with less ecofriendly impact, Fig.S2.</p><sec id="Sec29"><title><italic>First derivative method (</italic><sup><italic>1</italic></sup><italic>D)</italic></title><p id="Par36">By utilizing Excel software to differentiate absorbance data with respect to &#x003bb;, <sup>1</sup>D (dA/d&#x003bb;) signals could be generated. Generally, these signals have distinct maxima or minima and could be used to determine single analytes&#x02014;by crossing zero points.</p><p id="Par37">The effect of wavelength interval, &#x02206;&#x003bb;, was investigated in order to achieve the highest sensitive <sup>1</sup>D signals with least noise amount. It was determined that a 2&#x000a0;nm wavelength interval was suitable. The process of differentiating zero order spectra produced <sup>1</sup>D, with a peak of TAD at 294&#x000a0;nm with a zero crossing of MIR, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. The direct determination of MIR using <sup>1</sup>D method was not achievable in the presence of TAD.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Overlaid of <sup>1</sup>D plots for MIR &#x00026; TAD at four concentrations (1,5, 10 and 20 &#x000b5;g/mL) for each component</p></caption><graphic xlink:href="13065_2025_1497_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec30"><title>Fourier function convolution spectrophotometry (A/FF)</title><p id="Par38">First, eight points trigonometric FF, with a 1&#x000a0;nm interval, were used to convolute both MIR and TAD spectra using excel software. Displaying the computed coefficients as a function of &#x003bb;&#x000a0;resulted in convoluted spectra, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. This figure showed that MIR could be determined at 252&#x000a0;nm, when TAD's contribution was nil while TAD could be computed at 292&#x000a0;nm, a zero MIR contribution.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Overlaid of A/FF plots for MIR &#x00026; TAD at three concentrations (1,5, and 10 &#x000b5;g/mL) for each component</p></caption><graphic xlink:href="13065_2025_1497_Fig4_HTML" id="MO4"/></fig></p><p id="Par39">Calibration curves as well as the regression equations were computed by relating the FF coefficients, calculated at the selected points, to the respective component concentrations.</p><p id="Par40">Applying FF convolution to&#x000a0;various spectral data types is very helpful in removing various interferences and eliminating spectral overlap [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Thus, Fourier functions could potentially be&#x000a0;employed as a more accurate substitute for derivative spectrophotometry. Even at low concentrations, Fourier function convolution may be quite helpful in solving binary mixes with substantially overlapping spectra because of its ability to remove various interferences. High levels of selectivity for a certain drug with minimal interference from other compounds are guaranteed by choosing the function type, quantity of data points, and wavelength interval optimally.</p></sec><sec id="Sec31"><title><italic>Ratio derivative spectrophotometry (R</italic>.<sup><italic>1</italic></sup><italic>D)</italic></title><p id="Par41">To get ratio spectra, absorption spectra were divided either by 1&#x000a0;&#x003bc;g/mL TAD, which was used for the selective measurement of MIR, or by 10&#x000a0;&#x003bc;g/mL MIR, which was used for the selective determination of TAD.</p><p id="Par42">The magnitude of the ratio spectra is mostly determined by the divisor concentration, which is why several concentrations of TAD (1, 5, and 10&#x000a0;&#x003bc;g/mL) and MIR (1, 5, 10, and 15&#x000a0;&#x003bc;g/mL) were investigated. The concentrations of the divisors, 1&#x000a0;&#x003bc;g/mL TAD and 10&#x000a0;&#x003bc;g/mL MIR, were chosen according to the lowest noise level and the highest sensitivity.</p><p id="Par43">Plotting the estimated ratio derivative spectra versus wavelength resulted in the appropriate convoluted curves, Figs. <xref rid="Fig5" ref-type="fig">5</xref> and <xref rid="Fig6" ref-type="fig">6</xref>. Figure&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref> made it evident that the coefficients chosen at peak-to-peak measurements of 246 and 258&#x000a0;nm could be used to determine the concentration of MIR whereas Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref> showed that the coefficients at peak-to-peak measurements of &#x003bb; 287 and 297&#x000a0;nm were corresponding to the concentration of TAD.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Overlaid <italic>R</italic><sup><italic>1</italic></sup><italic>D</italic> spectra of MIR at 1, 5, 10 &#x003bc;g/mL with synthetic mixtures of different ratios divided by 1 &#x000b5;g/mL TAD</p></caption><graphic xlink:href="13065_2025_1497_Fig5_HTML" id="MO5"/></fig><fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Overlaid<italic> R</italic><sup><italic>1</italic></sup><italic>D</italic> spectra of TAD at1, 5, 10 &#x003bc;g/mL TAD with synthetic mixtures of different ratios divided by 10 &#x000b5;g/mL MIR</p></caption><graphic xlink:href="13065_2025_1497_Fig6_HTML" id="MO6"/></fig></p><p id="Par44">This approach used points of coincidence across the spectra of the binary mixture&#x000a0;and the standard solution of only one compound with the same concentration to determine the working wavelengths, Fig. S1. This makes peak-to-peak results feasible, which raises the analytical signals' sensitivity.</p></sec></sec><sec id="Sec32"><title>Chromatographic optimization</title><p id="Par45">The goal of the suggested HPLC technique was to create a valid chromatographic system that could separate and elute MIR and TAD simultaneously. The following experimental parameters were adjusted to optimize the analytical process's sensitivity and selectivity.</p><sec id="Sec33"><title>Stationary phase</title><p id="Par46">A variety of stationary phases were tested. Both MIR and TAD peaks were eluted lately using C<sub>8</sub> and C<sub>18</sub> (5 &#x000b5;m, 250&#x02009;&#x000d7;&#x02009;4.6 mm) columns, whereas they were successfully separated within short run time using a C<sub>18</sub> (3.5 &#x000b5;m, 100&#x02009;&#x000d7;&#x02009;4.6 mm) column.</p></sec><sec id="Sec34"><title>Organic modifier</title><p id="Par47">The peak form of both medications under investigation was significantly influenced by the type of organic modifier. A variety of organic solvents, including ACN, MeOH, and EtOH, had been explored. Peak broadening, reduced efficiency, and shape distortion of the MIR and TAD peaks were the results of using EtOH in the mobile phase. The use of ACN caused MIR to be eluted relatively early, causing its peak to be overlapped with the solvent front. However, the elution of MIR and TAD with a suitable peak shape for both and retention time for MIR was made possible by the use of MeOH.</p><p id="Par48">The mobile phase containing varying amounts of MeOH (0%, 25%, 50%, 60%, and 80%) was used to inject binary drug combinations, Table S1. Initially, 60% MeOH was chosen for separation resulting in a reasonable elution of MIR (2 min) but late TAD elution (10 min) with high tailing factor. Higher ratio of MeOH caused rapid elution of MIR near the solvent front. Trying ACN instead of MeOH resulted in a very rapid elution of MIR with solvent front even though reasonable elution of TAD had been achieved. So, gradient elution was eventually used with 60% MeOH for the first three min, then the percentage was increased to 80% for 2 min to achieve optimum separation with reasonable retention times for both peaks, Table S1. At 5 min, the system returned to the initial ratio of the mobile phase to permit column equilibration before the next injection.</p></sec><sec id="Sec35"><title>pH of the aqueous phase</title><p id="Par49">The impact of the eluent's aqueous component's pH was examined. A range of pH values (2.0&#x02013;7.0) with 10 mM phosphate buffer (modified by sodium hydroxide or orthophosphoric acid), in conjunction with MeOH in the previously mentioned gradient system, were tested.</p><p id="Par50">The best resolution of the cited drugs was ideally achieved using pH of 7 matching the pKa values of both drugs; MIR 13.84, 9.62 and TAD 15.17, -4.2, from drug bank. Additionally, TEA was incorporated to the aqueous portion as a competitive base to TAD and thus improved peak tailing.</p></sec><sec id="Sec36"><title>Detection wavelength</title><p id="Par51">Various wavelengths were tested for the quantification of the suggested drugs for the sake of improving the method's sensitivity. The best sensitivity was gained with detection at 250 nm for MIR and 225 nm for TAD.</p><p id="Par52">Peak sharpness and resolution within acceptable runtime, Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a, demonstrates the notable separation of MIR and TAD. Table <xref rid="Tab1" ref-type="table">1</xref> demonstrates that the system suitability parameters of the chromatographic separation of our binary method meets the FDA guidelines [<xref ref-type="bibr" rid="CR33">33</xref>].<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>HPLC chromatograms of 50 &#x000b5;g/mL of MIR and TAD <bold>a</bold> without degradation, using <bold>b</bold> alkaline, <bold>c</bold> acidic, <bold>d</bold> peroxide, <bold>e</bold> water, <bold>f</bold> light and <bold>g</bold> dry heat stress conditions</p></caption><graphic xlink:href="13065_2025_1497_Fig7_HTML" id="MO7"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>System suitability parameters for the HPLC&#x02013;DAD determination of MIR and TAD<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">MIR (250&#x000a0;nm)</th><th align="left">TAD (225&#x000a0;nm)</th></tr></thead><tbody><tr><td align="left">t<sub>R</sub>&#x02009;&#x000b1;&#x02009;SD (min)<sup>b</sup></td><td align="left">2.21&#x000a0;min&#x02009;&#x000b1;&#x02009;0.01</td><td align="left">4.52&#x000a0;min&#x02009;&#x000b1;&#x02009;0.01</td></tr><tr><td align="left">Plates (N)</td><td align="left">2181</td><td align="left">2505</td></tr><tr><td align="left">Resolution<sup>c</sup></td><td align="left" colspan="2">8.09</td></tr><tr><td align="left">Capacity factor (k')</td><td align="left">1.12</td><td align="left">3.67</td></tr><tr><td align="left">Tailing Factor</td><td align="left">1.05</td><td align="left">0.98</td></tr><tr><td align="left">Selectivity factor (&#x003b1;)</td><td align="left" colspan="2">3.28</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>System suitability recommendations: k' (1&#x02013;10), N&#x02009;&#x0003e;&#x02009;2000, &#x003b1;&#x02009;&#x0003e;&#x02009;1, R<sub>s</sub>&#x02009;&#x0003e;&#x02009;2 and T<sub>f</sub> (0.8 -1.2)[<xref ref-type="bibr" rid="CR39">39</xref>]</p><p><sup>b</sup>Average t<sub>R</sub>&#x02009;&#x000b1;&#x02009;SD of three determinations</p><p><sup>c</sup>Resolution between MIR and TAD</p></table-wrap-foot></table-wrap></p></sec></sec></sec><sec id="Sec37"><title>Methods validation</title><p id="Par53">Validation of our suggested methods was done in consistent with ICH standards [<xref ref-type="bibr" rid="CR34">34</xref>] as follows:</p><sec id="Sec38"><title>Linearity, limit of detection (LOD) and limit of quantitation (LOQ)</title><p id="Par54">The calculated concentrations of MIR and TAD were related to the computed values for A/FF, R<sup>1</sup>D or HPLC area for both drugs, as well as <sup>1</sup>D for TAD only, each of which was chosen at the previously set wavelength and chromatographic conditions. Regression coefficient values (r) for each of the recommended methods were higher than 0.999, suggesting a boosted degree of linearity as shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Moreover, the linearity range in HPLC method was wider than spectrophotometric ones, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, as the linearity range in spectrophotometer is limited to a narrow absorbance range, 0.3&#x02013;0.9. LOD and LOQ of MIR and TAD were determined as stated in ICH recommendations [<xref ref-type="bibr" rid="CR34">34</xref>], Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. HPLC minimizes background noise by separating interfering substances before detection, leading to better signal clarity. Thus, LOD and LOQ of HPLC method were about 100 times lower than those of spectrophotometric methods, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Analytical performance data of spectrophotometric and HPLC methods for MIR and TAD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Analyte</th><th align="left" colspan="3">MIR</th><th align="left" colspan="4">TAD</th></tr><tr><th align="left">Method</th><th align="left">A/FF</th><th align="left">R<sup>1</sup>D</th><th align="left">HPLC</th><th align="left"><sup>1</sup>D</th><th align="left">A/FF</th><th align="left">R<sup>1</sup>D</th><th align="left">HPLC</th></tr></thead><tbody><tr><td align="left">Wavelength (nm)</td><td align="left">252</td><td align="left">246 &#x00026; 258</td><td align="left">250</td><td align="left">294</td><td align="left">292</td><td align="left">287&#x00026;297</td><td align="left">225</td></tr><tr><td align="left">Linearity Range (&#x000b5;g/mL)</td><td align="left" colspan="2">1&#x02013;20</td><td align="left">0.85&#x02013;100</td><td align="left" colspan="3">1&#x02013;20</td><td align="left">0.65&#x02013;100</td></tr><tr><td align="left">LOD (&#x000b5;g/mL)</td><td align="left">3.18 <inline-formula id="IEq1"><alternatives><tex-math id="d33e1025">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1030"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">2.83 <inline-formula id="IEq2"><alternatives><tex-math id="d33e1043">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1048"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">1.31 <inline-formula id="IEq3"><alternatives><tex-math id="d33e1061">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-3}$$\end{document}</tex-math><mml:math id="d33e1066"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq3.gif"/></alternatives></inline-formula></td><td align="left">3.24 <inline-formula id="IEq4"><alternatives><tex-math id="d33e1079">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1084"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">2.95 <inline-formula id="IEq5"><alternatives><tex-math id="d33e1097">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1102"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">2.65 <inline-formula id="IEq6"><alternatives><tex-math id="d33e1115">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1120"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">3.41 <inline-formula id="IEq7"><alternatives><tex-math id="d33e1133">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-3}$$\end{document}</tex-math><mml:math id="d33e1138"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq3.gif"/></alternatives></inline-formula></td></tr><tr><td align="left">LOQ (&#x000b5;g/mL)</td><td align="left">9.64 <inline-formula id="IEq8"><alternatives><tex-math id="d33e1154">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1159"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">8.59 <inline-formula id="IEq9"><alternatives><tex-math id="d33e1172">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1177"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">3.97 <inline-formula id="IEq10"><alternatives><tex-math id="d33e1190">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-3}$$\end{document}</tex-math><mml:math id="d33e1195"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq3.gif"/></alternatives></inline-formula></td><td align="left">9.83 <inline-formula id="IEq11"><alternatives><tex-math id="d33e1208">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1213"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">8.93 <inline-formula id="IEq12"><alternatives><tex-math id="d33e1226">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1231"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">8.04 <inline-formula id="IEq13"><alternatives><tex-math id="d33e1244">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1249"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">1.13 <inline-formula id="IEq14"><alternatives><tex-math id="d33e1262">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-2}$$\end{document}</tex-math><mml:math id="d33e1267"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq14.gif"/></alternatives></inline-formula></td></tr><tr><td align="left">Correlation coefficient</td><td align="left">0.9993</td><td align="left">0.9994</td><td align="left">0.9996</td><td align="left">0.9996</td><td align="left">0.9997</td><td align="left">0.9998</td><td align="left">0.9996</td></tr><tr><td align="left">Slope</td><td align="left">3.77 <inline-formula id="IEq15"><alternatives><tex-math id="d33e1300">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-3}$$\end{document}</tex-math><mml:math id="d33e1305"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq3.gif"/></alternatives></inline-formula></td><td align="left">1.83</td><td align="left">3.11 <inline-formula id="IEq16"><alternatives><tex-math id="d33e1320">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{1}$$\end{document}</tex-math><mml:math id="d33e1325"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>1</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq16.gif"/></alternatives></inline-formula></td><td align="left">4.78 <inline-formula id="IEq17"><alternatives><tex-math id="d33e1336">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-3}$$\end{document}</tex-math><mml:math id="d33e1341"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq3.gif"/></alternatives></inline-formula></td><td align="left">2.72 <inline-formula id="IEq18"><alternatives><tex-math id="d33e1354">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-3}$$\end{document}</tex-math><mml:math id="d33e1359"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq3.gif"/></alternatives></inline-formula></td><td align="left">1.78</td><td align="left">5.49 <inline-formula id="IEq19"><alternatives><tex-math id="d33e1374">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{1}$$\end{document}</tex-math><mml:math id="d33e1379"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>1</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq16.gif"/></alternatives></inline-formula></td></tr><tr><td align="left">SE of slope</td><td align="left">6.00 <inline-formula id="IEq20"><alternatives><tex-math id="d33e1393">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-5}$$\end{document}</tex-math><mml:math id="d33e1398"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq20.gif"/></alternatives></inline-formula></td><td align="left">2.75 <inline-formula id="IEq21"><alternatives><tex-math id="d33e1411">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-2}$$\end{document}</tex-math><mml:math id="d33e1416"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq14.gif"/></alternatives></inline-formula></td><td align="left">6.67 <inline-formula id="IEq22"><alternatives><tex-math id="d33e1429">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1434"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">7.00 <inline-formula id="IEq23"><alternatives><tex-math id="d33e1447">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-5}$$\end{document}</tex-math><mml:math id="d33e1452"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq20.gif"/></alternatives></inline-formula></td><td align="left">3.00 <inline-formula id="IEq24"><alternatives><tex-math id="d33e1465">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-5}$$\end{document}</tex-math><mml:math id="d33e1470"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq20.gif"/></alternatives></inline-formula></td><td align="left">1.68 <inline-formula id="IEq25"><alternatives><tex-math id="d33e1483">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-2}$$\end{document}</tex-math><mml:math id="d33e1488"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq14.gif"/></alternatives></inline-formula></td><td align="left">1.93</td></tr><tr><td align="left">Intercept</td><td align="left">2.00 <inline-formula id="IEq26"><alternatives><tex-math id="d33e1506">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-5}$$\end{document}</tex-math><mml:math id="d33e1511"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq20.gif"/></alternatives></inline-formula></td><td align="left">-2.32 <inline-formula id="IEq27"><alternatives><tex-math id="d33e1524">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1529"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">1.18 <inline-formula id="IEq28"><alternatives><tex-math id="d33e1542">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{1}$$\end{document}</tex-math><mml:math id="d33e1547"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>1</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq16.gif"/></alternatives></inline-formula></td><td align="left">-1.44 <inline-formula id="IEq29"><alternatives><tex-math id="d33e1558">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-3}$$\end{document}</tex-math><mml:math id="d33e1563"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq3.gif"/></alternatives></inline-formula></td><td align="left">-1.08 <inline-formula id="IEq30"><alternatives><tex-math id="d33e1576">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-3}$$\end{document}</tex-math><mml:math id="d33e1581"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq3.gif"/></alternatives></inline-formula></td><td align="left">-4.91 <inline-formula id="IEq31"><alternatives><tex-math id="d33e1594">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1599"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">-3.41</td></tr><tr><td align="left">SE of intercept</td><td align="left">3.60 <inline-formula id="IEq32"><alternatives><tex-math id="d33e1617">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-4}$$\end{document}</tex-math><mml:math id="d33e1622"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq32.gif"/></alternatives></inline-formula></td><td align="left">1.57 <inline-formula id="IEq33"><alternatives><tex-math id="d33e1635">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1640"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">1.63 <inline-formula id="IEq34"><alternatives><tex-math id="d33e1653">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{1}$$\end{document}</tex-math><mml:math id="d33e1658"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mn>1</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq16.gif"/></alternatives></inline-formula></td><td align="left">4.70 <inline-formula id="IEq35"><alternatives><tex-math id="d33e1669">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-4}$$\end{document}</tex-math><mml:math id="d33e1674"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq32.gif"/></alternatives></inline-formula></td><td align="left">2.40 <inline-formula id="IEq36"><alternatives><tex-math id="d33e1687">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-4}$$\end{document}</tex-math><mml:math id="d33e1692"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq32.gif"/></alternatives></inline-formula></td><td align="left">1.43 <inline-formula id="IEq37"><alternatives><tex-math id="d33e1705">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times {10}^{-1}$$\end{document}</tex-math><mml:math id="d33e1710"><mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left">6.42</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>average of three determinations</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec39"><title>Accuracy and precision</title><p id="Par55">The assay of MIR and TAD synthetic combinations, covering the linearity range with various ratios confirmed the validity of the suggested procedures. Good mean % recoveries (100&#x02009;&#x000b1;&#x02009;2%) along with optimum % RSD (not exceed 2%), Table S2, indicated excellent accuracy alongside with precision of the proposed methods for all mixture ratios, including the challenging ratio of the dosage form 10:1.</p></sec><sec id="Sec40"><title>Selectivity</title><p id="Par56">Selectivity was evaluated in MIR and TAD using tablets&#x02019; extract, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, to ensure absence of interferences from excipients in the tablets. Both spectrophotometric and chromatographic methods showed superior percentage mean recoveries (100%&#x02009;&#x000b1;&#x02009;2) for both MIR and TAD, with relative SD values (&#x000b1;&#x02009;2%) in all different&#x000a0;ratios. Additionally, in HPLC, DAD was used to determine peak purity, which guarantees MIR and TAD peaks purity, Fig. S3. The above-mentioned results guaranteed methods&#x02019; selectivity.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Assay of MIR and TAD in laboratory prepared tablets using the proposed methods</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="3">MIR</th><th align="left" colspan="4">TAD</th></tr><tr><th align="left">Method</th><th align="left">A/FF</th><th align="left">R<sup>1</sup>D</th><th align="left">HPLC</th><th align="left"><sup>1</sup>D</th><th align="left">A/FF</th><th align="left">R<sup>1</sup>D</th><th align="left">HPLC</th></tr></thead><tbody><tr><td align="left">Mean <inline-formula id="IEq38"><alternatives><tex-math id="d33e1788">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pm$$\end{document}</tex-math><mml:math id="d33e1793"><mml:mo>&#x000b1;</mml:mo></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq38.gif"/></alternatives></inline-formula> SD</td><td align="left">99.55 <inline-formula id="IEq39"><alternatives><tex-math id="d33e1800">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pm$$\end{document}</tex-math><mml:math id="d33e1805"><mml:mo>&#x000b1;</mml:mo></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq38.gif"/></alternatives></inline-formula> 1.25</td><td align="left">100.22 <inline-formula id="IEq40"><alternatives><tex-math id="d33e1812">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pm$$\end{document}</tex-math><mml:math id="d33e1817"><mml:mo>&#x000b1;</mml:mo></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq38.gif"/></alternatives></inline-formula> 0.93</td><td align="left">99.20 <inline-formula id="IEq41"><alternatives><tex-math id="d33e1824">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pm$$\end{document}</tex-math><mml:math id="d33e1829"><mml:mo>&#x000b1;</mml:mo></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq38.gif"/></alternatives></inline-formula> 0.99</td><td align="left">99.97 <inline-formula id="IEq42"><alternatives><tex-math id="d33e1836">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pm$$\end{document}</tex-math><mml:math id="d33e1841"><mml:mo>&#x000b1;</mml:mo></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq38.gif"/></alternatives></inline-formula> 0.98</td><td align="left">100.95 <inline-formula id="IEq43"><alternatives><tex-math id="d33e1848">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pm$$\end{document}</tex-math><mml:math id="d33e1853"><mml:mo>&#x000b1;</mml:mo></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq38.gif"/></alternatives></inline-formula> 1.35</td><td align="left">99.56 <inline-formula id="IEq44"><alternatives><tex-math id="d33e1860">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pm$$\end{document}</tex-math><mml:math id="d33e1865"><mml:mo>&#x000b1;</mml:mo></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq38.gif"/></alternatives></inline-formula> 1.20</td><td align="left">101.12 <inline-formula id="IEq45"><alternatives><tex-math id="d33e1872">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pm$$\end{document}</tex-math><mml:math id="d33e1877"><mml:mo>&#x000b1;</mml:mo></mml:math><inline-graphic xlink:href="13065_2025_1497_Article_IEq38.gif"/></alternatives></inline-formula> 0.96</td></tr><tr><td align="left">Er%</td><td align="left">&#x02212;&#x000a0;0.45</td><td align="left">0.23</td><td align="left">&#x02212;&#x000a0;0.80</td><td align="left">&#x02212;&#x000a0;0.03</td><td align="left">0.95</td><td align="left">&#x02212;&#x000a0;0.44</td><td align="left">1.12</td></tr><tr><td align="left">F calculated</td><td align="left" colspan="3">1.43</td><td align="left" colspan="4">2.66</td></tr><tr><td align="left">F critical</td><td align="left" colspan="3">3.68</td><td align="left" colspan="4">3.10</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec41"><title>Robustness of the HPLC method</title><p id="Par57">By assessing MIR and TAD at the same concentration levels as previously mentioned but with other parameters (temperature, wavelength and pH) that were slightly altered, as shown in table S3, the robustness of the suggested approaches was evaluated.</p><p id="Par58">It was discovered that minor intentional adjustments to the parameters had no discernible impact on the assay of MIR and TAD. Satisfactory robustness shown by nearly unchanged responses (peak areas 100&#x02009;&#x000b1;&#x02009;2%), and/or retention times (SD&#x02009;&#x02264;&#x02009;2%) values of both MIR and TAD in the HPLC method.</p></sec></sec><sec id="Sec42"><title>Analysis of dosage forms</title><p id="Par59">The suggested techniques were applied for quantification of both drugs in their dosage forms. The concentrations of MIR and TAD were calculated from their corresponding regression equations. Single factor: One-way ANOVA [<xref ref-type="bibr" rid="CR35">35</xref>] was used for statistical comparison, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. There was no discernible difference between the approaches because the computed F values of 1.43 for MIR, and 2.66 for TAD did not surpass the critical values of 3.68 and 3.10, respectively.</p></sec><sec id="Sec43"><title>Stability-indicating study</title><p id="Par60">The stability-indicating capability of the HPLC method was evaluated by subjecting MIR and TAD to various forced degradation conditions, including oxidative, thermal, photolytic, neutral, acidic, and alkaline stress, in accordance with ICH Q1A(R2) guidelines [<xref ref-type="bibr" rid="CR36">36</xref>]. The results demonstrated that MIR and TAD remained stable under oxidative, thermal, light, and neutral conditions, as no significant degradation products were observed, and peak purity remained intact, Figs, 7 and Table S4. However, under acidic and alkaline hydrolysis, TAD exhibited remarkable stability, while MIR underwent 58.5% and 47.2% degradation, respectively, forming additional peaks at 1, 1.2 and 1.8 min. corresponding to degradation products (DPs), Figs, 7. The peak purity analysis confirmed that the method effectively separated DPs from the parent MIR, validating its stability-indicating nature, Table S4. The degradation of MIR under acidic and alkaline conditions was most likely attributed to the hydrolysis of the amide group and thus suggests its susceptibility to acidic and alkaline breakdown, emphasizing the need for controlled pH conditions in formulations and storage. However, the degradation patterns of the medications as a mixture and as singles did not differ, suggesting that these drugs could be safely used together. Moreover, the obtained stability results were in accordance with previously reported literature [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. These findings confirm that the developed HPLC method is selective, reliable, and suitable for stability studies, ensuring accurate quality control of MIR-TAD combination therapy.</p></sec><sec id="Sec44"><title>Trio colored assessment, greenness, blueness and whiteness, of the proposed analytical methods</title><p id="Par61">Environmental methods have recently drawn more attention in a variety of analytical techniques, such as chromatography [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], and spectroscopy [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref>]. Additionally, the three-color-coded methodology provides a comprehensive evaluation of every analytical step [<xref ref-type="bibr" rid="CR42">42</xref>]. The concerns of environmental safety as well as sustainable development objectives must be addressed by the analytical procedure.</p><sec id="Sec45"><title>Greenness assessment</title><p id="Par62">Based on the twelve green analytical chemistry (GAC) foundations, AGREE [<xref ref-type="bibr" rid="CR43">43</xref>] which is a free greenness evaluation tool, was released in June 2020. A fraction of one represents the overall score in AGREE, which goes from zero (lowest green) to one (highest green). The twelve parts that make up the automatically created pictogram each have a unique fundamental hue that varies from deep green to deep red depending on how well it matches the greenness. Our proposed procedures received eco-friendliness grades of 0.66 and 0.56 for spectrophotometric and chromatographic methods, respectively, out of 1 from the AGREE tool, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. The difference in the scores between the two methods is attributed to the used diluting solvent, water, which is greener than MeOH, the organic mobile phase in HPLC method. Moreover, lower energy consumption along with higher sample numbers contributed to the increased spectrophotometry AGREE value over HPLC. Thus, the suggested approaches closely complied with its greenness attribute, according to the results, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Comparison of the greenness, blueness and whiteness profiles of the proposed methods</p></caption><graphic position="anchor" xlink:href="13065_2025_1497_Tab4_HTML" id="MO8"/></table-wrap></p></sec><sec id="Sec46"><title>Blueness assessment</title><p id="Par63">GAC shouldn&#x02019;t be the only criteria we ought to be taking into consideration before selecting a method. The method's applicability and practicality are equally significant. The red&#x02013;green&#x02013;blue (RGB) model, which integrates a method's ecological, analytical, and practical components and encompasses the "White Analytical Chemistry" concept (WAC), served as the model's inspiration for the color "blue" [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par64">By taking into consideration ten important parameters:&#x000a0;analysis type, analytes number, the instrumentation, the sample preparation requirements, the sample throughput, the number of analyzed samples per hour, the required chemicals and/or materials, automation degree, and the needed sample amount, BAGI enables a thorough assessment of the applicability or blueness of an analytical procedure. Each of these ten parameters is graded on a scale from 1 (worst) to 10 (best).</p><p id="Par65">The composite BAGI score is computed as the geometric mean of the results for the ten distinct categories. An analytical technique with a higher BAGI score is considered more relevant, useful, and suitable for the purpose for which it is designed. With a high BAGI score of 70 and 75 for spectrophotometric and chromatographic methods, respectively, the proposed approaches demonstrated good blueness, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. BAGI different scores between two methods is attributed to the small sample size needed for HPLC (10 &#x000b5;L) versus 3mL in spectrophotometry. Although BAGI review demonstrates that our approaches are very effective in terms of general functioning, hazard reduction, and time and cost savings, it is not able to provide a complete, thorough assessment of sustainability.</p></sec><sec id="Sec47"><title>Whiteness assessment</title><p id="Par66">The RGB12 model, introduced in 2021, marked the transition from green to white as a descriptor for analytical approaches, facilitated by an open-access, ready-to-use Excel spreadsheet. This WAC assessment tool&#x000a0;is separated into three main color areas: red, green, and blue. The analytical efficiency is assessed in the red area using the validation criteria of sensitivity, accuracy, and precision. While the blue region evaluates performance using criteria including operational simplicity, cost-effectiveness, time efficiency, and lowest practical requirements, the green region gives GAC principles. The final score shows the whiteness percentage of the approach after calculating the arithmetic mean of the three regions following the evaluation of all RGB12 model parameters. Up to ten techniques can be evaluated and compared at once using the template. As our methods are the first ones for determination this synergistic combination, we used RGB12 model for comparison between them [<xref ref-type="bibr" rid="CR45">45</xref>].</p><p id="Par67">Every parameter is graded in relation to the best-performing approach. For example, the proposed HPLC method overwhelmed the spectrophotometric one in redness, 95 and 85, respectively, due to wider linearity range, lower LOD and LOQ beside higher robustness of the HPLC method, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. On the other hand, as in AGREE, RGB12 greenness was higher using spectrophotometric techniques than the HPLC due to usage of greener solvent (water versus MeOH), lower waste volume (3 versus 6 mL), and lower energy consumption (due to shorter analysis time, 30 samples/h versus 10 samples/h), respectively, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. In RGB12 blueness, the proposed spectrophotometric method gained higher score, 93.8, than the proposed HPLC one, 85. This was contradicted with BAGI results despite they pursuit the same goal: practicality of the method. We attributed this to the different evaluation elements in each of them beside self-assessment of RGB12 unlike automated BAGI. Nevertheless, the whiteness final score of both methods was higher than 85% which ensures sustainability of our methods, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>.</p><p id="Par68">Looking to Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, RGB12 blueness score favors spectrophotometry over HPLC, contradicting the BAGI score due to different weighing factors used for each evaluation. RGB12 blueness evaluation depends on the average of four criteria&#x02019;s: cost-efficiency, time-efficiency, requirements and operational simplicity giving the upper hand to the spectrophotometric method. While BAGI evaluation depends on ten criterions mentioned in Sect.&#x000a0;"<xref rid="Sec39" ref-type="sec">Blueness assessment</xref>" making it more powerful applicability evaluation tool beside its automation and HPLC was then bluer than the other methods.</p></sec></sec><sec id="Sec48"><title>Spider diagram used to evaluate the solvent's greenness index</title><p id="Par69">In our newly suggested spectrophotometric and HPLC methods, water and MeOH Greenness Index was assessed with spider diagram to evaluate the solvents used in each method, respectively. This tool depends on information obtained from safety data sheets (SDSs), which reveal details regarding a solvent's characteristics. A visual depiction of the overall sustainability degree for the chemicals utilized was created by combining five assessment criterion subcategories (health impact, fire safety, odor, overall characteristics, and stability) into a hierarchy spider diagram.</p><p id="Par70">These criteria produced values that varied from &#x02212;&#x000a0;5 to&#x02009;+&#x02009;5. For each of the five previously listed subcategories, there are further spider charts that include extra information. Due to the fact that various chemical reagents do not offer all of the data required for the five aforementioned subgroups on a single SDS, the computation assigned a score of 0 to the missing data. The reliability of the greenness rating is demonstrated by these references. [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]</p><p id="Par71">This spider method makes it possible to visually assess reagents, which simplifies and clarifies the thorough study of water and MeOH that were required for our procedures. Water has a positive average score of 4.16 on the major spider chart, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, indicating that it is safe for both the environment and human health. This value is much higher than that of MeOH, 0.89. This explains why H<sub>2</sub>O is preferable than MeOH when giving similar sensitivities. The secondary spider diagrams in Fig. S4 a&#x02013;d show the supporting information for the other scores. The percentage of relevant data and average scores for water and MeOH are illustrated in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> of the Greenness Index.</p><p id="Par72">The Spider Greenness Index technique offers a visual illustration of the solvent greenness comparison by elucidating the associated sub-points with each greenness requirement. However, this makes it challenging to adopt because it necessitates individual effort and requires reading through a large number of SDSs to find the most useful information, this makes it difficult to adopt.</p></sec><sec id="Sec49"><title><italic>Insilico</italic> prediction of severity of DDIs</title><p id="Par73">Drugs with cytochrome P450 (CYP) activity can act as substrates, inducers, or inhibitors of specific CYP enzymatic pathways, hence modifying the drugs&#x02019; metabolism that are supplied concurrently. Drugs that inhibit the CYP enzymatic pathway could produce medication toxicity due to a potential elevation in the plasma level of CYP substrates. Drugs that initiate a CYP enzymatic route can also cause drugs metabolized by the same process to have lower plasma concentration levels, which can lead to subtherapeutic levels of drug or unsatisfactory treatment outcomes. Most of the hepatic metabolism has been linked to the CYP enzymes coming from families 1, 2, or 3. Approximately 79% of the oxidation of these drugs was attributed to the most commonly engaged pathways, which included CYP2C9, CYP2D6, CYP2C19, and CYP3A4/5. Concurrent pharmaceutical therapy may result in drug-drug interactions. Therefore, comprehending the CYP system is vital to the safety of medications. [<xref ref-type="bibr" rid="CR48">48</xref>]</p><p id="Par74">DDIs mediated by CYP450 were assessed when the structures of the two compounds, TAD and MIR, were added to the Way2drug portal [<xref ref-type="bibr" rid="CR49">49</xref>]<bold>.</bold> The likelihood of DDI at each individual enzyme level in the CYP450 class is indicated by the <italic>IAP</italic> data. The <italic>IAP</italic> is the Invariant Accuracy of Prediction which means the difference among the inactive probability "to be inactive" (Pi) and the active probability "to be active" (Pa) in DDIs mediated by CYP450. This value was calculated for the studied drugs. If <italic>IAP</italic> values are negative, this indicates that Pi&#x02009;&#x0003e;&#x02009;Pa as well as, quite likely, the drugs in question do not have any DDI at the cytochrome level. However, if <italic>IAP</italic> is positive and less than 0.7, there may be insufficient proof of DDI and it can be disregarded. But there is a considerable chance of DDI if <italic>IAP</italic> results are positive and more than 0.7.</p><p id="Par75">Leave-one-out cross-validation (LOO CV) procedure is performed using the whole PASS training set for validation of prediction quality. Biological activity spectrum is predicted for each compound using the structure&#x02013;activity relationships calculated from the data for all other compounds. The prediction result is compared with known experimental data for the studied compound. The procedure is repeated for all compounds from the PASS training set; then the average Invariant Accuracy of Prediction (IAP) values are calculated for each biological activity and for all biological activities.</p><p id="Par76">As shown in Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>, there was no interaction between TAD and MIR at the seven CYP450 enzymes. The values of <italic>IAP</italic> were -0.391, -0.012, -0.519, -0.77, -0.811, -0.702, and -0.33 for CYP3A4, CYP2D6, CYP2C9, CYP2C8, CYP2C19, CYP2B6, and CYP1A2, respectively, Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>. The ORCA system assessed the level of severity&#x000a0;of DDIs and found that class 5, which denotes no interaction, was the case.<fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>Diagram showing <italic>IAP</italic> values of DDIs between MIR and TAD at the level of the seven CYP450 enzymes</p></caption><graphic xlink:href="13065_2025_1497_Fig8_HTML" id="MO9"/></fig></p><p id="Par77">Moreover, the adverse effects due to concomitant administration were evaluated and all Pa values were lower than Pi ones. As activities for a given side effect are only deemed potential if Pa&#x02009;&#x0003e;&#x02009;Pi, this indicates no probability of interactions while coadministration of MIR and TAD, Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>. [<xref ref-type="bibr" rid="CR48">48</xref>]<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Possible DDI adverse events due to concomitant use of MIR and TAD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Activity</th><th align="left">Pa</th><th align="left">Pi</th></tr></thead><tbody><tr><td align="left">DDI arrhythmia</td><td char="," align="char">0,015</td><td char="," align="char">0,667</td></tr><tr><td align="left">DDI bradycardia</td><td char="," align="char">0,068</td><td char="," align="char">0,368</td></tr><tr><td align="left">DDI hypertension</td><td char="," align="char">0,075</td><td char="," align="char">0,259</td></tr><tr><td align="left">DDI hypotension</td><td char="," align="char">0,079</td><td char="," align="char">0,412</td></tr><tr><td align="left">DDI qt_interval_prolongation</td><td char="," align="char">0,018</td><td char="," align="char">0,664</td></tr><tr><td align="left">DDI tachycardia</td><td char="," align="char">0,050</td><td char="," align="char">0,291</td></tr></tbody></table></table-wrap></p><p id="Par78">Therefore, MIR and TAD could be safely supplied together at the <italic>insilico</italic> level without compromising their pharmacokinetic properties. Our <italic>insilico</italic> approach, which guides but does not replace in vitro or in vivo research, can aid in prioritizing drug development efforts and initiates studies for polypills manufacturing possibilities.</p></sec></sec><sec id="Sec50"><title>Conclusion</title><p id="Par79">In conclusion, the developed analytical methods for the simultaneous determination of MIR and TAD in their combination therapy using spectrophotometry and HPLC offer highly reliable and environmentally sustainable solutions. Both methods were validated and demonstrated excellent performance in terms of precision, accuracy, and sensitivity, making them suitable for routine quality control applications. Moreover, the stability-indicating HPLC method successfully differentiated degradation products, confirming its suitability for stability studies. The assessment of these methods through green chemistry evaluation tools, such as AGREE, RGB12, and BAGI, confirms their eco-friendly nature, contributing to the advancement of sustainable analytical practices. Additionally, the use of artificial intelligence via an online tool to ensure the absence of DDIs further strengthens the safety profile of this combination therapy. Overall, this study provides a comprehensive, innovative approach to the analytical determination of MIR and TAD, ensuring their effective and safe use in clinical practice while promoting sustainability in pharmaceutical analysis.</p></sec><sec id="Sec51" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13065_2025_1497_MOESM1_ESM.docx"><caption><p>Supplementary material 1.</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>S.A. and R.Y. wrote the main manuscript text and H.M and M.A. prepared figures and tables. S.A. made the graphical abstract. S.A., R.Y., H.M and M.A. reviewed the manuscript and contribute to the conception, design of the work; the acquisition, analysis, interpretation of data; the creation of new software used in the work; have drafted the work or substantively revised it. All authors have approved the submitted version.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data are available upon request from the authors.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par80">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par81">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par82">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Michel</surname><given-names>MC</given-names></name></person-group><article-title>Editorial: benign prostatic hyperplasia and overactive bladder: new members of metabolic syndrome</article-title><source>Front Urol</source><year>2023</year><pub-id pub-id-type="doi">10.3389/fruro.2023.1272592</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Wang X, Yu Q, Michel MC. Editorial: benign prostatic hyperplasia and overactive bladder: new members of metabolic syndrome. Front Urol. 2023. 10.3389/fruro.2023.1272592.</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Kok</surname><given-names>ET</given-names></name><etal/></person-group><article-title>Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study</article-title><source>J Urol</source><year>2009</year><volume>181</volume><issue>2</issue><fpage>710</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2008.10.025</pub-id><pub-id pub-id-type="pmid">19091352</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Kok ET, et al. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol. 2009;181(2):710&#x02013;6.<pub-id pub-id-type="pmid">19091352</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Dmochowski</surname><given-names>RR</given-names></name><name><surname>Gomelsky</surname><given-names>A</given-names></name></person-group><article-title>Overactive bladder in males</article-title><source>Ther Adv Urol</source><year>2009</year><volume>1</volume><issue>4</issue><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1177/1756287209350383</pub-id><pub-id pub-id-type="pmid">21789068</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Dmochowski RR, Gomelsky A. Overactive bladder in males. Ther Adv Urol. 2009;1(4):209&#x02013;21.<pub-id pub-id-type="pmid">21789068</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>O</given-names></name><etal/></person-group><article-title>Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men</article-title><source>Int J Urol</source><year>2013</year><volume>20</volume><issue>2</issue><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1111/j.1442-2042.2012.03130.x</pub-id><pub-id pub-id-type="pmid">22958078</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Yokoyama O, et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. Int J Urol. 2013;20(2):193&#x02013;201.<pub-id pub-id-type="pmid">22958078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Ichihara</surname><given-names>K</given-names></name><etal/></person-group><article-title>A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction</article-title><source>J Urol</source><year>2015</year><volume>193</volume><issue>3</issue><fpage>921</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2014.09.091</pub-id><pub-id pub-id-type="pmid">25254938</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Ichihara K, et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015;193(3):921&#x02013;6.<pub-id pub-id-type="pmid">25254938</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanishi</surname><given-names>T</given-names></name><etal/></person-group><article-title>A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study)</article-title><source>Neurourol Urodyn</source><year>2020</year><volume>39</volume><issue>2</issue><fpage>804</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1002/nau.24285</pub-id><pub-id pub-id-type="pmid">31961963</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Yamanishi T, et al. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourol Urodyn. 2020;39(2):804&#x02013;12.<pub-id pub-id-type="pmid">31961963</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy of combination treatment with Tadalafil and Mirabegron in patients with benign prostatic hyperplasia who presented with persistent storage symptoms after tadalafil monotreatment: a prospective, multicenter</article-title><source>Open-Labeled Study Yonago Acta Med</source><year>2022</year><volume>65</volume><issue>3</issue><fpage>231</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.33160/yam.2022.08.009</pub-id><pub-id pub-id-type="pmid">36061573</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Honda M, et al. Efficacy of combination treatment with Tadalafil and Mirabegron in patients with benign prostatic hyperplasia who presented with persistent storage symptoms after tadalafil monotreatment: a prospective, multicenter. Open-Labeled Study Yonago Acta Med. 2022;65(3):231&#x02013;7.<pub-id pub-id-type="pmid">36061573</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Latoz</surname><given-names>C</given-names></name><name><surname>Larkin</surname><given-names>L</given-names></name><name><surname>Huynh-Ba</surname><given-names>K</given-names></name></person-group><article-title>Stability considerations for drug-device combination products-21 CFR part 4 update</article-title><source>AAPS Open</source><year>2023</year><volume>9</volume><issue>1</issue><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s41120-023-00078-5</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Latoz C, Larkin L, Huynh-Ba K. Stability considerations for drug-device combination products-21 CFR part 4 update. AAPS Open. 2023;9(1):10.</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Aboras</surname><given-names>SI</given-names></name><etal/></person-group><article-title>Hyphenating sustainability with chemometrics in chromatographic analysis of COVID combo therapy, nirmatrelvir and Molnupiravir, in presence of their overlapping degradation products; blue-green dual evaluation tools</article-title><source>J Chromatogr B</source><year>2024</year><volume>1247</volume><fpage>124304</fpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2024.124304</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Aboras SI, et al. Hyphenating sustainability with chemometrics in chromatographic analysis of COVID combo therapy, nirmatrelvir and Molnupiravir, in presence of their overlapping degradation products; blue-green dual evaluation tools. J Chromatogr B. 2024;1247: 124304.</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Sayed</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Earth-friendly-assessed UV-spectrophotometric approaches for concurrent determination of mirabegron and solifenacin succinate in different matrices</article-title><source>Sustain Chem Pharm</source><year>2023</year><volume>32</volume><fpage>100976</fpage><pub-id pub-id-type="doi">10.1016/j.scp.2023.100976</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Sayed RA, et al. Earth-friendly-assessed UV-spectrophotometric approaches for concurrent determination of mirabegron and solifenacin succinate in different matrices. Sustain Chem Pharm. 2023;32: 100976.</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Roopa</surname><given-names>KP</given-names></name><etal/></person-group><article-title>Development and Validation of Spectrophotometric Methods for the Assay of Mirabegron in Bulk and Pharmaceutical Formulations</article-title><source>J Appl Spectrosc</source><year>2021</year><volume>87</volume><issue>6</issue><fpage>1171</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1007/s10812-021-01126-2</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Roopa KP, et al. Development and Validation of Spectrophotometric Methods for the Assay of Mirabegron in Bulk and Pharmaceutical Formulations. J Appl Spectrosc. 2021;87(6):1171&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Farid</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Spectrofluorimetric methods for the determination of mirabegron by quenching tyrosine and L-tryptophan fluorophores: Recognition of quenching mechanism by stern volmer relationship, evaluation of binding constants and binding sites</article-title><source>Spectrochim Acta A Mol Biomol Spectrosc</source><year>2023</year><volume>293</volume><fpage>122473</fpage><pub-id pub-id-type="doi">10.1016/j.saa.2023.122473</pub-id><pub-id pub-id-type="pmid">36801734</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Farid NA, et al. Spectrofluorimetric methods for the determination of mirabegron by quenching tyrosine and L-tryptophan fluorophores: Recognition of quenching mechanism by stern volmer relationship, evaluation of binding constants and binding sites. Spectrochim Acta A Mol Biomol Spectrosc. 2023;293: 122473.<pub-id pub-id-type="pmid">36801734</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Morshedy</surname><given-names>S</given-names></name><etal/></person-group><article-title>Validated spectrofluorimetric method for determination of mirabegron by utilizing its quenching effect on acetoxymercuric fluorescein reagent</article-title><source>Spectrochim Acta A Mol Biomol Spectrosc</source><year>2020</year><volume>239</volume><fpage>118509</fpage><pub-id pub-id-type="doi">10.1016/j.saa.2020.118509</pub-id><pub-id pub-id-type="pmid">32502818</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Morshedy S, et al. Validated spectrofluorimetric method for determination of mirabegron by utilizing its quenching effect on acetoxymercuric fluorescein reagent. Spectrochim Acta A Mol Biomol Spectrosc. 2020;239: 118509.<pub-id pub-id-type="pmid">32502818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder</article-title><source>J Pharm Biomed Anal</source><year>2024</year><volume>240</volume><fpage>115937</fpage><pub-id pub-id-type="doi">10.1016/j.jpba.2023.115937</pub-id><pub-id pub-id-type="pmid">38198885</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Lou Y, et al. Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder. J Pharm Biomed Anal. 2024;240: 115937.<pub-id pub-id-type="pmid">38198885</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration</article-title><source>Rev Assoc Med Bras</source><year>2019</year><volume>65</volume><issue>2</issue><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1590/1806-9282.65.2.141</pub-id><pub-id pub-id-type="pmid">30892436</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Chen L, Zhang Y. Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration. Rev Assoc Med Bras. 2019;65(2):141&#x02013;8.<pub-id pub-id-type="pmid">30892436</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Meijer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Validation of LC-MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population</article-title><source>J Pharm Biomed Anal</source><year>2019</year><volume>167</volume><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2019.02.007</pub-id><pub-id pub-id-type="pmid">30776753</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Meijer J, et al. Validation of LC-MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population. J Pharm Biomed Anal. 2019;167:155&#x02013;60.<pub-id pub-id-type="pmid">30776753</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Konduru</surname><given-names>N</given-names></name><name><surname>Kowtharapu</surname><given-names>LP</given-names></name><name><surname>Gundla</surname><given-names>R</given-names></name></person-group><article-title>Unique liquid chromatography technique for the determination of mirabegron in the presence of polymers; robustness by design expert in the light of quality by design</article-title><source>Biomed Chromatogr</source><year>2022</year><volume>36</volume><issue>10</issue><fpage>e5449</fpage><pub-id pub-id-type="doi">10.1002/bmc.5449</pub-id><pub-id pub-id-type="pmid">35831974</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Konduru N, Kowtharapu LP, Gundla R. Unique liquid chromatography technique for the determination of mirabegron in the presence of polymers; robustness by design expert in the light of quality by design. Biomed Chromatogr. 2022;36(10): e5449. <pub-id pub-id-type="pmid">35831974</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Abou El-Alamin</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Development of Green HPTLC method for simultaneous determination of a promising combination Tamsulosin and Mirabegron: stability-indicating assay was examined</article-title><source>BMC Chem</source><year>2023</year><volume>17</volume><issue>1</issue><fpage>130</fpage><pub-id pub-id-type="doi">10.1186/s13065-023-01043-9</pub-id><pub-id pub-id-type="pmid">37777770</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Abou El-Alamin MM, et al. Development of Green HPTLC method for simultaneous determination of a promising combination Tamsulosin and Mirabegron: stability-indicating assay was examined. BMC Chem. 2023;17(1):130.<pub-id pub-id-type="pmid">37777770</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Mouhamed</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Design of screen-printed potentiometric platform for sensitive determination of mirabegron in spiked human plasma; molecular docking and transducer optimization</article-title><source>RSC Adv</source><year>2023</year><volume>13</volume><issue>33</issue><fpage>23138</fpage><lpage>23146</lpage><pub-id pub-id-type="doi">10.1039/D3RA02343E</pub-id><pub-id pub-id-type="pmid">37533779</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Mouhamed AA, et al. Design of screen-printed potentiometric platform for sensitive determination of mirabegron in spiked human plasma; molecular docking and transducer optimization. RSC Adv. 2023;13(33):23138&#x02013;46.<pub-id pub-id-type="pmid">37533779</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelazim</surname><given-names>AH</given-names></name><name><surname>Ramzy</surname><given-names>S</given-names></name></person-group><article-title>Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi capsules</article-title><source>BMC Chem</source><year>2022</year><volume>16</volume><issue>1</issue><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/s13065-022-00850-w</pub-id><pub-id pub-id-type="pmid">35906639</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Abdelazim AH, Ramzy S. Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi capsules. BMC Chem. 2022;16(1):55.<pub-id pub-id-type="pmid">35906639</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Ustundag</surname><given-names>I</given-names></name><name><surname>Caglayan</surname><given-names>MO</given-names></name></person-group><article-title>Spectroscopic determination of hydrophobic adulterant tadalafil by aptasensor based ellipsometry</article-title><source>Talanta</source><year>2024</year><volume>266</volume><issue>Pt 1</issue><fpage>124940</fpage><pub-id pub-id-type="doi">10.1016/j.talanta.2023.124940</pub-id><pub-id pub-id-type="pmid">37454513</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ustundag I, Caglayan MO. Spectroscopic determination of hydrophobic adulterant tadalafil by aptasensor based ellipsometry. Talanta. 2024;266(Pt 1): 124940.<pub-id pub-id-type="pmid">37454513</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Kammoun</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Development of validated methods for the simultaneous quantification of Finasteride and Tadalafil in newly launched FDA-approved therapeutic combination: greenness assessment using AGP, analytical eco-scale, and GAPI tools</article-title><source>RSC Adv</source><year>2023</year><volume>13</volume><issue>17</issue><fpage>11817</fpage><lpage>11825</lpage><pub-id pub-id-type="doi">10.1039/D3RA01437A</pub-id><pub-id pub-id-type="pmid">37077997</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Kammoun AK, et al. Development of validated methods for the simultaneous quantification of Finasteride and Tadalafil in newly launched FDA-approved therapeutic combination: greenness assessment using AGP, analytical eco-scale, and GAPI tools. RSC Adv. 2023;13(17):11817&#x02013;25.<pub-id pub-id-type="pmid">37077997</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Youssef</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Assay of new combination of tamsulosin and tadalafil using synchronous spectrofluorimetric method coupled with mathematical tools</article-title><source>Spectrochim Acta Part A Mol Biomol Spectroscopy</source><year>2022</year><volume>271</volume><fpage>120904</fpage><pub-id pub-id-type="doi">10.1016/j.saa.2022.120904</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Youssef MR, et al. Assay of new combination of tamsulosin and tadalafil using synchronous spectrofluorimetric method coupled with mathematical tools. Spectrochim Acta Part A Mol Biomol Spectroscopy. 2022;271:120904.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Elama</surname><given-names>HS</given-names></name><etal/></person-group><article-title>A synchronous spectrofluorometric technique for simultaneous detection of alfuzosin and tadalafil: applied to tablets and spiked biological samples</article-title><source>R Soc Open Sci</source><year>2022</year><volume>9</volume><issue>7</issue><fpage>220330</fpage><pub-id pub-id-type="doi">10.1098/rsos.220330</pub-id><pub-id pub-id-type="pmid">35845851</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Elama HS, et al. A synchronous spectrofluorometric technique for simultaneous detection of alfuzosin and tadalafil: applied to tablets and spiked biological samples. R Soc Open Sci. 2022;9(7): 220330.<pub-id pub-id-type="pmid">35845851</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Dual beta-cyclodextrin functionalized Au@SiC nanohybrids for the electrochemical determination of tadalafil in the presence of acetonitrile</article-title><source>Biosens Bioelectron</source><year>2015</year><volume>64</volume><fpage>126</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.bios.2014.08.068</pub-id><pub-id pub-id-type="pmid">25216449</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Yang L, et al. Dual beta-cyclodextrin functionalized Au@SiC nanohybrids for the electrochemical determination of tadalafil in the presence of acetonitrile. Biosens Bioelectron. 2015;64:126&#x02013;30.<pub-id pub-id-type="pmid">25216449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Naguib</surname><given-names>IA</given-names></name><etal/></person-group><article-title>A validated green HPTLC method for quantitative determination of dapoxetine hydrochloride and tadalafil in bulk and pharmaceutical formulations</article-title><source>J Chromatogr Sci</source><year>2020</year><volume>58</volume><issue>4</issue><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1093/chromsci/bmz115</pub-id><pub-id pub-id-type="pmid">31942957</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Naguib IA, et al. A validated green HPTLC method for quantitative determination of dapoxetine hydrochloride and tadalafil in bulk and pharmaceutical formulations. J Chromatogr Sci. 2020;58(4):303&#x02013;8.<pub-id pub-id-type="pmid">31942957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Tantawy</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Novel HPTLC densitometric methods for determination of tamsulosin HCl and tadalafil in their newly formulated dosage form: comparative study and green profile assessment</article-title><source>Biomed Chromatogr</source><year>2020</year><volume>34</volume><issue>8</issue><fpage>e4850</fpage><pub-id pub-id-type="doi">10.1002/bmc.4850</pub-id><pub-id pub-id-type="pmid">32302430</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Tantawy MA, et al. Novel HPTLC densitometric methods for determination of tamsulosin HCl and tadalafil in their newly formulated dosage form: comparative study and green profile assessment. Biomed Chromatogr. 2020;34(8): e4850.<pub-id pub-id-type="pmid">32302430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Aboras</surname><given-names>SI</given-names></name><etal/></person-group><article-title>HPLC/fluorescence-diode array detection for rapid and reliable determination of illegal synthetic drugs in male sexual herbal and honey remedies: comparative study with UFLC&#x02013;MS</article-title><source>J AOAC Int</source><year>2022</year><volume>105</volume><issue>5</issue><fpage>1288</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1093/jaoacint/qsac037</pub-id><pub-id pub-id-type="pmid">35298642</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Aboras SI, et al. HPLC/fluorescence-diode array detection for rapid and reliable determination of illegal synthetic drugs in male sexual herbal and honey remedies: comparative study with UFLC&#x02013;MS. J AOAC Int. 2022;105(5):1288&#x02013;98.<pub-id pub-id-type="pmid">35298642</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Ozturk</surname><given-names>EE</given-names></name><name><surname>Ozbek</surname><given-names>B</given-names></name><name><surname>Bakirdere</surname><given-names>S</given-names></name></person-group><article-title>Accurate and sensitive determination of sildenafil, tadalafil, vardenafil, and avanafil in illicit erectile dysfunction medications and human urine by LC with quadrupole-TOF-MS/MS and their behaviors in simulated gastric conditions</article-title><source>J Sep Sci</source><year>2019</year><volume>42</volume><issue>2</issue><fpage>475</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1002/jssc.201800734</pub-id><pub-id pub-id-type="pmid">30358113</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Ozturk EE, Ozbek B, Bakirdere S. Accurate and sensitive determination of sildenafil, tadalafil, vardenafil, and avanafil in illicit erectile dysfunction medications and human urine by LC with quadrupole-TOF-MS/MS and their behaviors in simulated gastric conditions. J Sep Sci. 2019;42(2):475&#x02013;83.<pub-id pub-id-type="pmid">30358113</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>L</given-names></name><name><surname>Halko</surname><given-names>R</given-names></name><name><surname>Hutta</surname><given-names>M</given-names></name></person-group><article-title>Fast ultra-high-performance liquid chromatography with diode array and mass spectrometry method for determination of tadalafil drug substance and its impurities</article-title><source>Biomed Chromatogr</source><year>2017</year><pub-id pub-id-type="doi">10.1002/bmc.4020</pub-id><pub-id pub-id-type="pmid">28558416</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Schreiber L, Halko R, Hutta M. Fast ultra-high-performance liquid chromatography with diode array and mass spectrometry method for determination of tadalafil drug substance and its impurities. Biomed Chromatogr. 2017. 10.1002/bmc.4020.<pub-id pub-id-type="pmid">28558416</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>El-Kimary</surname><given-names>EI</given-names></name><etal/></person-group><article-title>Fourier convolution versus derivative spectrophotometry: Application to the analysis of two binary mixtures containing tamsulosin hydrochloride as a minor component</article-title><source>Ann Pharm Fr</source><year>2020</year><volume>78</volume><issue>2</issue><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.pharma.2020.01.003</pub-id><pub-id pub-id-type="pmid">32070480</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">El-Kimary EI, et al. Fourier convolution versus derivative spectrophotometry: Application to the analysis of two binary mixtures containing tamsulosin hydrochloride as a minor component. Ann Pharm Fr. 2020;78(2):129&#x02013;41.<pub-id pub-id-type="pmid">32070480</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Youssef</surname><given-names>RM</given-names></name><name><surname>Maher</surname><given-names>HM</given-names></name></person-group><article-title>A new hybrid double divisor ratio spectra method for the analysis of ternary mixtures</article-title><source>Spectrochim Acta A Mol Biomol Spectrosc</source><year>2008</year><volume>70</volume><issue>5</issue><fpage>1152</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1016/j.saa.2007.10.049</pub-id><pub-id pub-id-type="pmid">18093870</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Youssef RM, Maher HM. A new hybrid double divisor ratio spectra method for the analysis of ternary mixtures. Spectrochim Acta A Mol Biomol Spectrosc. 2008;70(5):1152&#x02013;66.<pub-id pub-id-type="pmid">18093870</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">FDA, C.o.D.E.R.C. Reviewer guidance: validation of chromatographic methods, Washington, USA,. 2018 25/7/2022]; <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf">https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf</ext-link>.</mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">ICH, International Confernce on Harmonaisation (ICH), ICH, validation of analytical procedures: text and methodology, Q2(R1). 2005.</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Miller JN, Miller JC. Statistics and chemometrics for analytical chemistry, 6th Edition. 2010.</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">ICH, Stability testing of new drug substances and products Q1A(R2), International Conference on Harmonisation., February 2003.</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Gol</surname><given-names>D</given-names></name><etal/></person-group><article-title>Stability Indicating RP-HPLC-DAD method for simultaneous estimation of tadalafil and macitentan in synthetic mixture for treatment of pulmonary arterial hypertension</article-title><source>Ann Pharm Fr</source><year>2024</year><volume>82</volume><issue>3</issue><fpage>464</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.pharma.2023.10.006</pub-id><pub-id pub-id-type="pmid">37866638</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Gol D, et al. Stability Indicating RP-HPLC-DAD method for simultaneous estimation of tadalafil and macitentan in synthetic mixture for treatment of pulmonary arterial hypertension. Ann Pharm Fr. 2024;82(3):464&#x02013;72.<pub-id pub-id-type="pmid">37866638</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Aljohar</surname><given-names>HI</given-names></name><etal/></person-group><article-title>Development and comprehensive greenness assessment of HPLC method for quality control of &#x003b2;-sitosterol in pharmaceutical ointments with trio-color coded evaluation</article-title><source>BMC Chem</source><year>2025</year><volume>19</volume><issue>1</issue><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s13065-024-01372-3</pub-id><pub-id pub-id-type="pmid">39806491</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Aljohar HI, et al. Development and comprehensive greenness assessment of HPLC method for quality control of &#x003b2;-sitosterol in pharmaceutical ointments with trio-color coded evaluation. BMC Chem. 2025;19(1):14.<pub-id pub-id-type="pmid">39806491</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Aboras</surname><given-names>SI</given-names></name><etal/></person-group><article-title>Sustainable and technically smart spectrophotometric determination of PAXLOVID: a comprehensive ecological and analytical performance rating</article-title><source>BMC Chemistry</source><year>2024</year><volume>18</volume><issue>1</issue><fpage>184</fpage><pub-id pub-id-type="doi">10.1186/s13065-024-01275-3</pub-id><pub-id pub-id-type="pmid">39304939</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Aboras SI, et al. Sustainable and technically smart spectrophotometric determination of PAXLOVID: a comprehensive ecological and analytical performance rating. BMC Chemistry. 2024;18(1):184.<pub-id pub-id-type="pmid">39304939</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Kamal</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Penalization and color code technical approaches for method greenness and whiteness appraisal in veterinary medication: assay of toltrazuril suspension</article-title><source>J AOAC Int</source><year>2024</year><volume>107</volume><issue>6</issue><fpage>891</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1093/jaoacint/qsae063</pub-id><pub-id pub-id-type="pmid">39024015</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Kamal MF, et al. Penalization and color code technical approaches for method greenness and whiteness appraisal in veterinary medication: assay of toltrazuril suspension. J AOAC Int. 2024;107(6):891&#x02013;902.<pub-id pub-id-type="pmid">39024015</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>AEF</given-names></name><etal/></person-group><article-title>Application of machine learning assisted multi-variate UV spectrophotometric models augmented by kennard stone clustering algorithm for quantifying recently approved nasal spray combination of mometasone and olopatadine along with two genotoxic impurities: comprehensive sustainability assessment</article-title><source>BMC Chem</source><year>2025</year><volume>19</volume><issue>1</issue><fpage>98</fpage><pub-id pub-id-type="doi">10.1186/s13065-025-01391-8</pub-id><pub-id pub-id-type="pmid">40234857</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Abbas AEF, et al. Application of machine learning assisted multi-variate UV spectrophotometric models augmented by kennard stone clustering algorithm for quantifying recently approved nasal spray combination of mometasone and olopatadine along with two genotoxic impurities: comprehensive sustainability assessment. BMC Chem. 2025;19(1):98.<pub-id pub-id-type="pmid">40234857</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Ahmed AR, et al., Trio-colored appraisal of microwave-assisted synthesis of carbon quantum dots as a fluorescence turn off nanoprobe for analyzing Ledipasvir in tablets and rat feces: study of silymarin impact on excretion recovery. 2025. 40(3): e70138.</mixed-citation></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Pena-Pereira</surname><given-names>F</given-names></name><name><surname>Wojnowski</surname><given-names>W</given-names></name><name><surname>Tobiszewski</surname><given-names>M</given-names></name></person-group><article-title>AGREE&#x02014;analytical GREEnness metric approach and software</article-title><source>Anal Chem</source><year>2020</year><volume>92</volume><issue>14</issue><fpage>10076</fpage><lpage>10082</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.0c01887</pub-id><pub-id pub-id-type="pmid">32538619</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Pena-Pereira F, Wojnowski W, Tobiszewski M. AGREE&#x02014;analytical GREEnness metric approach and software. Anal Chem. 2020;92(14):10076&#x02013;82.<pub-id pub-id-type="pmid">32538619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Manousi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality</article-title><source>Green Chem</source><year>2023</year><volume>25</volume><issue>19</issue><fpage>7598</fpage><lpage>7604</lpage><pub-id pub-id-type="doi">10.1039/D3GC02347H</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Manousi N, et al. Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality. Green Chem. 2023;25(19):7598&#x02013;604.</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>PM</given-names></name><name><surname>Wietecha-Pos&#x00142;uszny</surname><given-names>R</given-names></name><name><surname>Pawliszyn</surname><given-names>J</given-names></name></person-group><article-title>White analytical chemistry: an approach to reconcile the principles of green analytical chemistry and functionality</article-title><source>TrAC Trends Anal Chem</source><year>2021</year><volume>138</volume><fpage>116223</fpage><pub-id pub-id-type="doi">10.1016/j.trac.2021.116223</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Nowak PM, Wietecha-Pos&#x00142;uszny R, Pawliszyn J. White analytical chemistry: an approach to reconcile the principles of green analytical chemistry and functionality. TrAC Trends Anal Chem. 2021;138: 116223.</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Development of greenness index as an evaluation tool to assess reagents: evaluation based on sds (safety data sheet) information</article-title><source>Miner Eng</source><year>2016</year><volume>94</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.mineng.2016.04.015</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Shen Y, et al. Development of greenness index as an evaluation tool to assess reagents: evaluation based on sds (safety data sheet) information. Miner Eng. 2016;94:1&#x02013;9.</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Lotfy</surname><given-names>HM</given-names></name><name><surname>Obaydo</surname><given-names>RH</given-names></name><name><surname>Nessim</surname><given-names>CK</given-names></name></person-group><article-title>Spider chart and whiteness assessment of synergistic spectrophotometric strategy for quantification of triple combination recommended in seasonal influenza&#x02014;detection of spurious drug</article-title><source>Sustain Chem Pharm</source><year>2023</year><volume>32</volume><fpage>100980</fpage><pub-id pub-id-type="doi">10.1016/j.scp.2023.100980</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Lotfy HM, Obaydo RH, Nessim CK. Spider chart and whiteness assessment of synergistic spectrophotometric strategy for quantification of triple combination recommended in seasonal influenza&#x02014;detection of spurious drug. Sustain Chem Pharm. 2023;32: 100980.</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>McDonnell</surname><given-names>AM</given-names></name><name><surname>Dang</surname><given-names>CH</given-names></name></person-group><article-title>Basic review of the cytochrome p450 system</article-title><source>J Adv Pract Oncol</source><year>2013</year><volume>4</volume><issue>4</issue><fpage>263</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">25032007</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">McDonnell AM, Dang CH. Basic review of the cytochrome p450 system. J Adv Pract Oncol. 2013;4(4):263&#x02013;8.<pub-id pub-id-type="pmid">25032007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">DDI-Pred. Web service for drug-drug interaction predection. <ext-link ext-link-type="uri" xlink:href="https://www.way2drug.com/ddi/">https://www.way2drug.com/ddi/</ext-link>. Accessed 29 Jan 2025.</mixed-citation></ref></ref-list></back></article>